Immuno-chemotherapy for infants with B-lineage ALL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of medicines (immunotherapy plus chemotherapy) in babies diagnosed with a type of leukemia called B-lineage acute lymphoblastic leukemia (ALL). It aims to improve how well treatment works and is delivered safely in very young children.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby was diagnosed between 1 and 365 days old
- Treatment starts soon after the clinic enrolls your family
- The leukemia is confirmed in bone marrow as ALL, not a different cancer
- This study is for B-lineage ALL and does not include Burkitt ALL
- Your parent/guardian can give informed consent and join the study clinics
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
This trial tests a treatment plan for adults aged 18 to 65 who have just been diagnosed with a type of acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome (Ph-negative). The goal is to see how well this therapy works and how safe it is.
This Phase 3 trial studies a treatment plan for people up to age 45 who are newly diagnosed with B-cell or T-cell acute lymphoblastic leukemia (ALL). The goal is to see whether the study treatment improves outcomes compared with standard approaches.
This trial tests a treatment plan for children with newly diagnosed acute lymphoblastic leukemia (ALL) that is considered standard-risk. It aims to see if the treatment is effective and safe.
This trial tests a standard treatment plan (a protocol) for people aged 0 to under 46 with newly diagnosed ALL, a cancer of the blood and bone marrow. It may help by making sure patients receive the right therapy based on their specific ALL subtype.
This trial tests a new treatment approach for children and teens with high-risk acute lymphoblastic leukemia (ALL). It aims to improve outcomes for those with certain genetic changes or cancer that has spread.
Hear when a new Acute Lymphoblastic Leukemia, Pediatric trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.